AGN
Allergan plc
NYSE
People also watch:BIIBCELGVRXGILDREGN
248.981.14 (0.46%)

After hours: 248.01-0.97 (-0.39%) as of 6:57 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close247.84
Open248.50
Bid248.82 x 800
Ask248.91 x 100
52wk Range195.50 - 340.34
Day's Range247.78 - 249.75
Volume1,962,936
Avg Vol (3m)3,574,328
As of 4:02 PM EDT. Market closed.
  • Reuters3 days ago

    Investors scrap for Teva Pharmaceutical bonds

    Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market. Investors had been making space for the well-telegraphed deal ever since Teva announced its US$40.5bn acquisition of Allergan Generics earlier in the year, while declining rates across the developed world and a lack of recent supply in the US and European markets added impetus to the transaction. In Europe, Teva issued bonds that priced up to 35bp inside its secondary curve - and those outstanding bonds, in turn, tightened by an incredible 40bp during the execution process.

  • The Wall Street Journal3 days ago

    Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin

    Amgen and Allergan on said a late-stage trial of their treatment being developed as a biosimilar to Roche’s breast cancer drug Herceptin met its primary endpoint.